ARTICLE | Clinical News

Andrx Phase III Metformin XT data

October 24, 2001 7:00 AM UTC

ADRX said data from two Phase III diabetes trials showed once-daily dosing of its Metformin XT extended release metformin had a similar safety and efficacy profile to Glucophage metformin, which is marketed by Bristol-Myers (BMY) and is dosed 2 or 3 times daily. ADRX said it expects to submit an NDA for the product to the FDA in the first half of 2002. ...